# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹1,297 Cr** Q2 FY'26 (+34% YoY, +7% QoQ) * **Gross Margin:** **65.7%** Q2 FY'26 (+368 bps YoY, +82 bps QoQ) * EBITDA: ₹2,782 Mn (21.5% of sales) Q2 FY'26 (+42 bps YoY, +106 bps QoQ) * R&D Expenses: ₹70.5 Cr (5.4% of sales) Q2 FY'26 * Net Debt: ₹10,241 Mn (₹1,024.1 Cr) Q2 FY'26 (from ₹9,480 Mn in Q1) * Cash Flow from Operations: ₹193.7 Cr Q2 FY'26 (vs. ₹280.6 Cr in Q1) ## B. Revenue Growth * **Strong Global Momentum:** Robust double-digit year-on-year and sequential revenue growth fueled by formulation business expansion in North America and Europe. ## C. Gross Margin * **Margin Acceleration:** Significant gross margin expansion driven by operational efficiency gains and a favorable product mix shift. ## D. EBITDA Profitability * **Profitability Leverage:** EBITDA margin improved meaningfully on strong sales growth and cost optimization, despite a **₹200 Cr loss** from Ascelis peptides. * **Management Commentary:** EBITDA margins approached near-optimal levels, suggesting limited headroom for further upside under current operating conditions. ## E. Balance Sheet & Cash Flow * **Investment Phase:** Rising net debt reflects elevated CAPEX, while R&D spend remains stable at **4% of sales** to support long-term innovation. * **Working Capital Stability:** Cash-to-cash cycle remained largely flat at **204 days**, indicating steady working capital management. * **Consulting Spend:** H1 FY'26 consultancy expenses totaled **$4 million**, consistent with ongoing strategic initiatives. --- # 2. Manufacturing & Site Progress ## A. Regulatory & Remediation Progress * **Final-Stage FDA Remediation:** Gagillapur facility is in the final stages of U.S. FDA remediation following the August 2024 inspection and warning letter, with all required actions on track and monthly progress reports ongoing. * **International Compliance Regained:** Site has secured GMP certifications from **German and Danish authorities**, passed **eight customer audits with zero critical findings**, and received the **UL certificate**, signaling strong global compliance recovery. * **Production Pause Impact:** Voluntary suspension of Gagillapur production in Q2 FY'25—despite FDA allowing continuation—impacted prior-year comparability but enabled proactive compliance demonstration. * **Post-Remediation Growth Path:** Remediation expected to conclude imminently, paving the way for new product approvals and resumption of growth momentum. ## B. FDA & EU Approval Milestones * **First FDA Approval for GLS Site:** Genome Valley facility received its first U.S. FDA product approval following a PAI in July–August 2025, unlocking **RX product manufacturing** and expanding finished dosage capacity. * **Chantilly GPI Site EIR Received:** U.S. FDA completed unannounced pre-approval inspection in June 2025 for a first-to-file controlled substance ANDA, advancing pipeline progress. * **Bonthapally API Unit 1 Classified VAI:** FDA issued Voluntary Action Indicated classification post-June 2025 inspection, indicating minor observations requiring corrective actions. * **Upcoming EU Inspection:** GLS Genome Valley site is scheduled for European regulatory inspection in the coming quarters, a key step toward broader market access. ## C. Capacity Optimization Strategy * **Product Transfer Evaluation:** Company is assessing transfer of select products from Gagillapur to Genome Valley to optimize utilization, though no formal timelines have been disclosed. --- # 3. Product & Segment Performance ## A. Key Figures * **Ascelis Revenue:** **₹28–29 Cr** quarterly turnover * **Ascelis EBITDA:** **(₹20 Cr)** loss, primarily from Senn Chemicals ## B. US & EU Formulations * **Growth Reacceleration:** US and EU formulation businesses are back on track, supported by remediation success, supply normalization, and strong momentum from US manufacturing. * **Diversified Growth Drivers:** Near-term performance fueled by CNS-ADHD expansion in the US, large-volume product scale-up, European value-chain progression, and upcoming oncology monetization from Vizag. * **Market Share Gains:** Granules is expanding share on legacy approvals (2–3 years post-launch), now contributing meaningfully to North America revenue growth. * **Base Effect Benefit:** Year-on-year growth amplified by prior-year USFDA-related plant shutdown, though underlying execution remains strong. ## C. Controlled Substances * **Stable Foundation, Long-Term Potential:** Controlled substances show stable H1 performance and are positioned as the **third growth pillar**, with a robust pipeline filed through 2035. * **Launch Timeline:** Near-term visibility includes 1–2 tentative approvals, but major commercialization remains 2–3 years out due to patent and first-to-file dynamics. ## D. Peptide CDMO Business * **Strategic Buildout:** Ascelis is emerging as a differentiated peptide CDMO, combining **Swiss R&D (Senn Chemicals)**, **Indian-scale manufacturing**, and global IP protection. * **Operational Milestone:** The **Peptide R&D Centre of Excellence at IIT Hyderabad** is operational, enhancing innovation capacity. * **Near-Term P&L Impact:** Ascelis integration has led to a **₹20 Cr EBITDA loss**, now fully absorbed; costs expected to stabilize barring new hiring. * **High-Growth Expectations:** Despite small current base, management anticipates **multiple-fold revenue expansion**, not linear growth, driven by global pharma and biotech interest. --- # 4. Capacity & Utilization ## A. Key Figures * Formulation Capacity: +10 billion doses (40% increase) from Genome Valley greenfield facility · 26 billion doses existing capacity at Gagillapur ## B. US Manufacturing Output * **Capacity Mitigation:** Revenue impact from domestic constraints partially offset by higher output at the **US manufacturing unit** and OTC supply from GLS facility. ## C. Greenfield Facility Scale-up * **Strategic Expansion:** FDA approval unlocks significant incremental capacity and establishes **second-source supply of finished dosages and PFIs to the U.S. from India**, enhancing supply chain resilience and export scalability. --- # 5. Customer & Pipeline Metrics ## A. Monograph Supply Ramp-up * **Commercial Momentum:** Supplies of monograph products to the U.S. have commenced, with a ramp-up in prescription product shipments expected post-FDA approval. ## B. New Product Filings * **Pipeline Acceleration:** Removal of the Gagillapur facility from the warning letter will unlock approvals for **4 to 5 new products**, including CB-30, enabling further revenue expansion. * **Capacity Strategy:** Approved products will be transferred from Gagillapur to meet growing demand, leveraging existing infrastructure for scale. ## C. Global Innovator Engagement * **Strategic Partnerships:** Engagement with global innovators is accelerating, driven by **LPPS hybrid chemistry capabilities** and **India-scale manufacturing**, particularly attracting early-stage biotechs seeking agility and cost efficiency. * **Differentiated Offerings:** **Senn Chemical’s TFA-free peptide technology** is a key differentiator in the European cosmetics market, enhancing appeal among brand owners. * **EU Expansion:** A new German subsidiary has been established to support **EU stocking and sales**, with plans for incremental growth. * **Forward-Looking Pipeline:** New business discussions are ongoing with innovators on clinical-stage assets, targeting project ramp-up from **FY2027 onward**, reinforcing long-term co-development strategy. --- # 6. Regulatory & Compliance Risks ## A. Regulatory Milestones & Engagement * **Re-inspection Process Initiated:** Granules India has achieved eligibility to request an FDA re-inspection and has scheduled a formal meeting with the agency for **January 2026 (Q4 FY'26)**, marking a critical step toward resolution. * **Proactive Compliance Credibility:** The voluntary operational pause has strengthened the company’s standing with the FDA, positioning it as a **highly compliant organization** in regulators’ eyes. * **No FDA Concerns on Testing:** The agency has raised no objections to the scope or speed of remediation, with **cross-contamination testing across 3,000+ samples showing zero failures** to date. ## B. Facility-Specific Progress * **Gagillapur Inspection Timeline Clarified:** The FDA re-inspection for Gagillapur is no longer anticipated in December 2025; post-meeting timing remains uncertain, but the company confirms it is fully prepared. * **Recent Approvals Signal Momentum:** Two facilities have secured recent compliance approvals, indicating broader regulatory progress across the network. ## C. Cost & Operational Impact * **Ongoing FDA Consultancy Spend:** Specialized regulatory advisory costs continue as part of remediation efforts, while core operational expenses remain stable post-Senn acquisition. --- # 7. Guidance & Outlook ## A. Key Figures * CAPEX Spend: ₹2.112 Cr Q2 FY26 · ₹1.137 Cr Q1 FY26 * **Investment in Peptide & Chemicals:** ₹450 Cr (acquisition) + ₹100 Cr (CAPEX) ## B. FY27 Revenue Trajectory * **Breakout Growth Ahead:** Management signals a return to **double-digit topline expansion from FY27**, driven by base business recovery and new peptide commercialization. * **Staggered Project Ramp-Up:** Revenue from pipeline projects will materialize **partially in FY27**, with longer-term contributions contingent on clinical program success. * **Sustained Revenue Visibility:** Ongoing commercial projects provide near-term revenue line of sight, supporting the upward trajectory. ## C. Peptide Profitability Path * **Q4 PAT Breakeven in Sight:** Peptide business on track for **PAT profitability by Q4**, driven by execution on existing commercial supply commitments, not new wins. * **Path to FY27 Sustainability:** Target remains **sustained profitability by FY27**, with initial project conversions expected within **6–18 months**. ## D. CAPEX & Project Timing * **Strategic Build-Out Underway:** CDMO transformation anchored in **complex and emerging peptides**, with CAPEX scaled **proportionally to project inflows** over a 1–3 year horizon. * **Consultancy Cost Windfall:** External consultancy expenses set to **fall sharply in H2 FY26** and approach **near-zero levels in FY27**, boosting margin potential. * **Post-Merger Integration Gains:** Close collaboration between Senn and Ascelis teams has strengthened **governance, quality, and operational execution**.